The paradox is simple: the more we spend on healthcare, the less we seem to get in health. That is not a moral failing. It is a design choice. When profits sit outside the clinic—in real estate, data sales, and government-adjacent subsidies—care becomes a cost center to be minimized. The financial machinery that Charles Hugh Smith spotlighted is not a side story. It is the operating system. Follow the money and the death spiral reads like a balance-sheet problem disguised as policy.
Hospitals do not mint their margins in operating rooms. They build them in commercial real estate, supply chain rebates, pharmacy spreads, and the monetization of patient health information. Care delivery is treated like a loss leader—necessary to qualify for the rents that come from being large, accredited, and politically connected. That is why corporate org charts skew toward property management and revenue cycle, not clinical improvement. Low rates made it painless to lever up for expansions and acquisitions; now higher rates have turned those gleaming towers into refinancing risks. When throughput stalls and debt service rises, executives push harder on off-balance-sheet profits: data brokering, vendor consolidation, and capturing government flow-throughs. This is the model—because that is where the money is.
Insurers now resemble regulated utilities. The Affordable Care Act’s medical loss ratio caps converted them into claims processors with admin fees. Value-based care was marketed as risk-sharing; in practice, Medicare Advantage turned into a coding contest. Risk scores went up faster than population morbidity. The inevitable audits, clawbacks, and prosecutions were not black swans; they were the logical endpoint of Goodhart’s Law. Measure something and it becomes the target. When your margin depends on labels, the business becomes labeling. As subsidies fade and late-pandemic care costs roll through, the balance sheets of mid-tier plans look thin. Consolidation is not a strategy; it is triage. The destination is fewer, larger administrators with less capacity or appetite to underwrite true risk.
The ACA aspired to a universal pool. Waivers, carve-outs, and patchwork subsidies made it optional for the healthy and unavoidable for the sick. That is not insurance. Insurance is the pooling of rare events, not the prepayment of near-certainties. As premium support wanes and deductibles rise, nonparticipation becomes rational for the young and solvent. The fixes—risk corridors, reinsurance, temporary subsidies—masked the math but did not change it. Game theory says the dominant strategy for a rational actor is to defer enrollment until the need materializes. In every market where that option exists, adverse selection is not a glitch; it is equilibrium. The result is a shrinking pool that costs more per head, pushing more healthy people out. Spiral confirmed.
A system optimized for average days fails on the worst days. We built a monoculture: consolidated suppliers, standardized IT, just-in-time staffing, centralized decision rights. It looked efficient. Then the pandemic severed throughput. Bailouts papered over the revenue hole, but they also trained boards to expect Washington backstops. That is fragility. In engineering terms, we removed redundancy to optimize for cost, creating single points of failure—EHR outages that halt care, a missing reagent that idles a lab, a closed rural ER that turns a stroke into a funeral. In nature, monocultures thrive—until a pathogen finds the seam. The US healthcare monoculture has many seams: cyber risk, supply concentration, debt rollover, and a workforce that is voting with its feet.
Capital does what we pay it to do. Private equity bought fragmented service lines, rolled them up, and steered referrals. Site-of-care differentials turned a clinic service into a hospital outpatient code with a price several times higher. Certificates of need and nonprofit tax shields limited new entrants. That is not a competitive market; it is a moat. Antitrust enforcement is catching up but remains episodic and slow relative to the pace of consolidation. We treat network effects in healthcare like a public good when they often behave like tollbooths. Where PE met lax oversight, staffing was cut to minimums, and assets were optimized for billing density, not resilience. That is efficient, right up until a tail event—an audit, a denial wave, a cyberattack—turns operating leverage into a cliff.
A parallel market is forming in the open. Direct primary care, transparent surgical bundles, and membership clinics offer cash prices and short waits. Meanwhile, wages inside the legacy system stagnate. Many clinicians and nurses are shifting to locums or agency work, taking control of their schedules and pay. That flow of talent is a price signal: labor is worth more outside the third-party maze. States that restrict cash-pay or ban clinician ownership block the release valve. Where the valve is open, the two-tier model hardens—fast access for those who can pay, wait lists for those who cannot. You can dislike it on moral grounds and still see the math: the cash market rewards outcomes and service; the third-party market rewards compliance and coding. In one, the patient is the customer. In the other, the payer is.
Investors have misread the last decade. They saw stable cash flows and called them defensible moats. Many were transfers from taxpayers, not proof of pricing power. That confusion created dangerous leverage. When the subsidy regime shifts—clawbacks in Medicare Advantage, stricter audits, curtailed add-on payments—the margins vanish while the debt remains. Narrative fallacy did the rest: if healthcare is noncyclical, then it must be safe. But noncyclical is not nonfragile. A cyberattack can halt admissions. A single regulatory change can erase a business line. One insurer’s network decision can collapse a practice. True risk is in the tails, and this system has fat tails. Robustness requires slack, redundancy, and skin in the game—three features our optimization binge removed.
This is not a call for another payment acronym. It is a design brief. If you pay for inputs, you will get more inputs. If you pay for labels, you will get better labels. Pay for outcomes you can audit, allow price discovery, and permit clinician ownership so decisions link to responsibility. Kill protectionist rules—certificate-of-need laws, bans on cash-pay arrangements—that entrench incumbents. Enforce antitrust in referral markets and data monopolies. Use catastrophic coverage to cap ruin and pair it with high-deductible plans and portable Health Savings Accounts so consumers see prices and providers see demand. Most important, decouple the profit engine from volume and coding. If a hospital’s solvency depends on real estate churn and data brokerage, it will never prioritize care delivery. Change the incentives and the org chart will change with them.
The United States did not stumble into a healthcare death spiral. It engineered one by rewarding scale over service, labels over outcomes, and debt-funded expansion over resilience. That is why the system keeps consolidating even as it fails. The fix is not a slogan or a subsidy. It is a rewiring of who gets paid for what and when. Markets adapt to incentives with ruthless precision. So does healthcare. Follow the money, and you can see where this goes next: fewer insurers acting as utilities, more private capital chasing nonclinical rents, and a growing cash market for those who can afford to bypass the maze. The only way to change the trajectory is to make care delivery the profit center again. Until then, we will keep spending more to buy fragility on credit.
